Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density
Phase 2
Completed
- Conditions
- Low Bone Mineral DensityPostmenopausal Osteoporosis
- Interventions
- First Posted Date
- 2009-05-11
- Last Posted Date
- 2022-09-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 419
- Registration Number
- NCT00896532
A High-resolution Peripheral Quantitative Computed Tomography Study in Postmenopausal Women Previously Treated With Denosumab
Phase 3
Completed
- Conditions
- Low Bone MassLow Bone Mineral DensityPostmenopausal OsteoporosisOsteoporosis
- Interventions
- Procedure: high-resolution peripheral quantitative computed tomography (HR-pQCT)Procedure: Dual energy X-ray absorptiometry (DXA)Biological: DenosumabDrug: Placebo
- First Posted Date
- 2009-04-30
- Last Posted Date
- 2014-04-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 79
- Registration Number
- NCT00890981
A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab
Phase 2
Completed
- Conditions
- Low Bone Mineral DensityOsteoporosisPostmenopausal OsteoporosisLow Bone Mass
- Interventions
- First Posted Date
- 2009-04-24
- Last Posted Date
- 2013-11-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 15
- Registration Number
- NCT00887965
A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols
- First Posted Date
- 2009-04-20
- Last Posted Date
- 2018-05-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 101
- Registration Number
- NCT00884312
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸The Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland, United States
A Study of Neutropenia and Anemia Management in Patients With Solid Tumors Receiving Myelotoxic Chemotherapy
Completed
- Conditions
- Ovarian CancerNon-Small Cell Lung CancerBreast CancerSmall Cell Lung Cancer
- First Posted Date
- 2009-04-17
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1370
- Registration Number
- NCT00883181
Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis
- First Posted Date
- 2009-03-31
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 9
- Registration Number
- NCT00872729
- Locations
- 🇺🇸
University of California San Diego Medical Center, San Diego, California, United States
A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer
Phase 2
Completed
- Conditions
- Inoperable Hepatocellular CarcinomaAdvanced Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2009-03-30
- Last Posted Date
- 2016-04-04
- Lead Sponsor
- Amgen
- Target Recruit Count
- 60
- Registration Number
- NCT00872014
A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease
- First Posted Date
- 2009-03-20
- Last Posted Date
- 2020-06-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 111
- Registration Number
- NCT00866359
- Locations
- 🇹🇷
Selçuk University, Konya, Turkey
🇺🇸Mayo Clinic - Rheumatology and Internal Medicine, Jacksonville, Florida, United States
🇺🇸Cleveland Clinic Foundation, Cleveland, Ohio, United States
Effects of Long-term Dosing of AMG 531 on Bone Marrow Morphology
Completed
- Conditions
- Idiopathic Thrombocytopenic Purpura
- Interventions
- Other: No Intervention for Observational Study
- First Posted Date
- 2009-03-13
- Last Posted Date
- 2010-07-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 10
- Registration Number
- NCT00861224
To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.
Phase 1
Completed
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2009-03-13
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 88
- Registration Number
- NCT00861419
© Copyright 2025. All Rights Reserved by MedPath